Phil is one of tranScrip’s experts in Translational Medicine, Clinical Pharmacology and Early Development having clinical training in Internal Medicine, and Clinical Pharmacology. Phil has worked in Early Development for 32 years, starting in CRO’s before joining Glaxo as Head of their Internal Clinical Pharmacology Unit. He spent 3 years working for a Biotech company and 15 years at Eli Lilly prior to joining tranScrip.
Phil has extensive experience of working with small molecules and Biopharmaceutics (monoclonal and bispecific antibodies, fusion proteins, Pegylated peptides and antibody-drug conjugates) and has worked in the majority of therapeutic areas. Phil’s main areas of interest are autoimmune diseases, diabetes, biomarker development and medical devices. He has also worked in rare disease indications such as haemophilia and demyelinating polyneuropathy. Phil also has broad experience of due diligence activities related to in-licensing and out-licensing as well as the application of PK/PD modelling and simulation to early phase development.
Whilst at Eli Lilly Phil chaired the Clinical Pharmacology Protocol Review Committee and was a member of the Pregnancy and Paediatric Safety Committee. Phil is a current member of the Faculty of Pharmaceutical Medicine’s Board of Examiners.